PUR 5700

Drug Profile

PUR 5700

Alternative Names: PUR-5700

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RespiVert
  • Developer Pulmatrix
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis

Most Recent Events

  • 13 Jun 2017 Pulmatrix in-licenses kinase inhibitor compounds from RespiVert
  • 29 Jan 2017 Preclinical trials in Asthma in USA (Inhalation)
  • 29 Jan 2017 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top